ONCO.ST
Price:
$2.075
Market Cap:
$438.37M
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.[Read more]
Industry
Biotechnology
IPO Date
2017-02-22
Stock Exchange
STO
Ticker
ONCO.ST
According to Oncopeptides AB (publ)’s latest financial reports and current stock price. The company's current Enterprise Value is 169.98M. This represents a change of -61.85% compared to the average of 445.60M of the last 4 quarters.
The mean historical Enterprise Value of Oncopeptides AB (publ) over the last ten years is 2.06B. The current 169.98M Enterprise Value has changed 726.03% with respect to the historical average. Over the past ten years (40 quarters), ONCO.ST's Enterprise Value was at its highest in in the December 2020 quarter at 7.30B. The Enterprise Value was at its lowest in in the June 2016 quarter at 0.
Average
2.06B
Median
1.18B
Minimum
103.01M
Maximum
6.72B
Discovering the peaks and valleys of Oncopeptides AB (publ) Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 266.89%
Maximum Annual Enterprise Value = 6.72B
Minimum Annual Increase = -98.47%
Minimum Annual Enterprise Value = 103.01M
Year | Enterprise Value | Change |
---|---|---|
2023 | 635.75M | 68.22% |
2022 | 377.92M | 266.89% |
2021 | 103.01M | -98.47% |
2020 | 6.72B | 78.98% |
2019 | 3.76B | 2.54% |
2018 | 3.66B | 102.74% |
2017 | 1.81B | 57.17% |
2016 | 1.15B | -3.20% |
2015 | 1.19B | 0.82% |
The current Enterprise Value of Oncopeptides AB (publ) (ONCO.ST) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
372.22M
5-year avg
2.32B
10-year avg
2.06B
Oncopeptides AB (publ)’s Enterprise Value is less than Hansa Biopharma AB (publ) (2.61B), less than BioArctic AB (publ) (12.40B), less than Calliditas Therapeutics AB (publ) (11.45B), less than Sinch AB (publ) (27.75B), less than Cantargia AB (publ) (460.87M),
Company | Enterprise Value | Market cap |
---|---|---|
2.61B | $2.22B | |
12.40B | $12.83B | |
11.45B | $11.24B | |
27.75B | $20.78B | |
460.87M | $545.55M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncopeptides AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Oncopeptides AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Oncopeptides AB (publ)'s Enterprise Value?
What is the highest Enterprise Value for Oncopeptides AB (publ) (ONCO.ST)?
What is the 3-year average Enterprise Value for Oncopeptides AB (publ) (ONCO.ST)?
What is the 5-year average Enterprise Value for Oncopeptides AB (publ) (ONCO.ST)?
How does the current Enterprise Value for Oncopeptides AB (publ) (ONCO.ST) compare to its historical average?